328 related articles for article (PubMed ID: 28273356)
21. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
22. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
Salinger DH; Endres CJ; Martin DA; Gibbs MA
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
Zhu Y; Hu C; Lu M; Liao S; Marini JC; Yohrling J; Yeilding N; Davis HM; Zhou H
J Clin Pharmacol; 2009 Feb; 49(2):162-75. PubMed ID: 19179295
[TBL] [Abstract][Full Text] [Related]
24. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
[TBL] [Abstract][Full Text] [Related]
25. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
[TBL] [Abstract][Full Text] [Related]
27. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.
Ohtsuki M; Morita A; Igarashi A; Imafuku S; Tada Y; Fujita H; Fujishige A; Yamaguchi M; Teshima R; Tani Y; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1105-1111. PubMed ID: 28543617
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
29. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases.
Tabrizi M; Wang B; Lu H; Huang S; Bell G; Schwab G; Roskos L
Inflamm Allergy Drug Targets; 2010 Sep; 9(4):229-37. PubMed ID: 20860546
[TBL] [Abstract][Full Text] [Related]
31. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Reich K; Papp KA; Matheson RT; Tu JH; Bissonnette R; Bourcier M; Gratton D; Kunynetz RA; Poulin Y; Rosoph LA; Stingl G; Bauer WM; Salter JM; Falk TM; Blödorn-Schlicht NA; Hueber W; Sommer U; Schumacher MM; Peters T; Kriehuber E; Lee DM; Wieczorek GA; Kolbinger F; Bleul CC
Exp Dermatol; 2015 Jul; 24(7):529-35. PubMed ID: 25828362
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
Endres CJ; Salinger DH; Köck K; Gastonguay MR; Martin DA; Klekotka P; Nirula A; Gibbs MA
J Clin Pharmacol; 2014 Nov; 54(11):1230-8. PubMed ID: 24846347
[TBL] [Abstract][Full Text] [Related]
33. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
34. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
35. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab.
Satoh Y; Nakano K; Yoshinari H; Nakayamada S; Iwata S; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Saito K; Tanaka Y
Lupus; 2018 Jun; 27(7):1202-1206. PubMed ID: 29523055
[TBL] [Abstract][Full Text] [Related]
36. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
[TBL] [Abstract][Full Text] [Related]
37. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor.
Kakkar T; Sung C; Gibiansky L; Vu T; Narayanan A; Lin SL; Vincent M; Banfield C; Colbert A; Hoofring S; Starcevic M; Ma P
Pharm Res; 2011 Oct; 28(10):2530-42. PubMed ID: 21604075
[TBL] [Abstract][Full Text] [Related]
38. Cedirogant Population Pharmacokinetics and Pharmacodynamic Analyses of Interleukin-17A Inhibition in Two Phase 1 Studies in Healthy Participants and Participants with Moderate to Severe Psoriasis.
Maier CS; Eckert D; Laroux FS; Hew KM; Suleiman AA; Liu W; Mohamed MF
Clin Pharmacol Drug Dev; 2024 May; 13(5):474-484. PubMed ID: 38231873
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis.
Li Q; Qiao J; Jin H; Chen B; He Z; Wang G; Ni X; Wang M; Xia M; Li B; Chen R; Hu P
Front Pharmacol; 2022; 13():966176. PubMed ID: 36052126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
